GEHC Earnings Prediction
The chart below shows how GEHC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, GEHC sees a +0.74% change in stock price 10 days leading up to the earnings, and a +0.01% change 10 days following the report. On the earnings day itself, the stock moves by -0.22%. This data can give you a slight idea of what to expect for the next quarter's release.
GEHC Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
4.86B
0.85%
0.50%
Gross Margin
41.64%
3.76%
0.65%
Operating Margin
15.46%
14.86%
5.82%
Net Margin
10.08%
26.00%
12.12%
EPS
1.02
24.39%
9.68%
No Data Available
GEHC Earnings Analysis
GE HealthCare Technologies Inc. Common Stock Corporation (GEHC.O) Earnings Conference Call
Positive
Organic Revenue Performance: In the third quarter, we delivered 1% organic revenue growth, in line with our expectations, with strong performance in the U.S. across all segments, and solid growth in Pharmaceutical Diagnostics.
Strong Backlog Increase: We exited the third quarter with a healthy backlog of $19.6 billion, up $1.2 billion year-over-year, and up $600 million sequentially.
Adjusted EBIT Margin Increase: We delivered an adjusted EBIT margin of 16.3%, up 90 basis points year-over-year, and ahead of our expectations.
Adjusted EPS Increase: Third quarter adjusted EPS was $1.14, up 15% year-over-year.
Free Cash Flow Increase: We generated free cash flow of $651 million, up $81 million year-over-year.
Negative
Organic Revenue Decline: In the third quarter, we delivered 1% organic revenue growth, which is a significant decline from the 6% organic revenue growth reported in the third quarter of 2023.
China Sales Decline: Reported sales growth in China was down over 20% in the quarter, contributing to a total company sales growth decline of approximately 400 basis points.
Organic Orders Slowdown: Organic orders growth was only 1% year-over-year, indicating a slowdown in demand across various segments.
Margin Performance Analysis: The overall margin performance in the quarter demonstrated ongoing cost optimization priorities, but this was against a backdrop of lower sales volumes than expected at the beginning of the year.
2024 Organic Revenue Outlook: We expect full-year 2024 organic revenue growth to trend toward the lower end of our 1% to 2% guidance due to continued softness in the China market.
GEHC FAQs
How does GEHC typically perform around its earnings report dates?
Is GE HealthCare Technologies Inc. (GEHC) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
GEHC Earning Call Sentiment
GE HealthCare Technologies Inc. (GEHC) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
GEHC.O
0.36%Positive
The earnings call summary presents mixed signals. Basic financial performance is weak with only 1% revenue growth and challenges in China, but margins and EPS are improving. Product development shows potential with new introductions, but competitive pressures and supply chain issues persist. Market strategy and expenses appear stable, with positive shareholder return plans. The Q&A reveals uncertainties, particularly in China and Flyrcado pricing. Despite strong EPS guidance, lowered revenue guidance tempers optimism. Without a market cap, a neutral prediction is prudent, balancing positive and negative factors.